Náuseas e vômitos induzidos por quimioterapia: Receptores 5-HT_3

5-HT3 receptor antagonists block serotonin receptors in the chemoreceptor trigger zone and vomiting center. When chemotherapy damages the GI mucosa, it releases serotonin that normally triggers vomiting via vagal nerves. By selectively blocking these 5-HT3 receptors, drugs like ondansetron and granisetron interrupt this signaling pathway, effectively preventing nausea and vomiting in chemotherapy patients.

The primary 5-HT3 antagonists include dolasetron, granisetron, ondansetron, and palonosetron. These drugs are available as tablets, oral solutions, and intravenous formulations for flexible administration. Palonosetron stands out with higher receptor affinity and a longer 40-hour half-life, providing extended symptom relief compared to other antagonists in this drug class.

Palonosetron exhibits higher affinity for 5-HT3 receptors and a significantly longer half-life of 40 hours compared to other antagonists. This extended duration allows for sustained receptor blockade with potentially fewer doses, making it particularly effective for preventing chemotherapy-induced nausea and vomiting over extended treatment periods.

Common adverse effects include headache, dizziness, and constipation. More serious concerns include QT interval prolongation, which can cause arrhythmias, particularly with high doses of dolasetron. Additionally, these drugs may cause serotonin syndrome when combined with other serotonergic medications, requiring careful drug interaction monitoring.

The liver extensively metabolizes 5-HT3 antagonists, with primary excretion through urine. Ondansetron requires dosage adjustments for patients with hepatic insufficiency to prevent drug accumulation. This hepatic metabolism pathway is clinically important when prescribing these drugs to patients with liver disease or those taking medications that affect liver function.

Yes, 5-HT3 antagonists can be combined with corticosteroids, neurokinin receptor antagonists, and dopamine receptor antagonists to enhance efficacy. These combination therapies target multiple pathways involved in nausea and vomiting, providing superior symptom control compared to monotherapy in patients undergoing chemotherapy.

5-HT3 antagonists act rapidly at their target sites and can be administered as a single dose before chemotherapy begins. This quick onset of action, combined with their availability in multiple formulations, makes them ideal for preemptive treatment of chemotherapy-induced nausea and vomiting in both chemotherapy and postoperative settings.